Video

Case report: butyric acid, bifidobacterium and fructooligosaccharides in a young patient with Rhoemheld syndrome

Vegim Zhaku, from Tetovo University Faculty of Medicine, Macedonia, discussed the case of a male patient with palpitations, shortness of breath, epigastric discomfort and flatulence.

FMT donors: the importance of gut metabolite screening

Sara Deleu, researcher at KU Leuven, talks about the role of gut metabolite, as Butyric acid and other compounds, during the fecal microbiota transplantation.

The ‘all biotic’ revolution: what is next and what do all these terms really mean?

George Paraskevakos, Executive Director at International Probiotics Association, discusses the future of the microbiome space.

Fecal Microbiota Transplantation: profiling of patients with pouchitis

Iris Dothan, from Rabin Medical Center, Israel, talks about the profiling of patient with pouchitis in order to determine the benefits from microbiome manipulation.

Live Biotherapeutics as cancer treatments: scientific and regulatory challenges

Jean-Luc Marsat, CEO & Chairman at EverImmune, discusses the research EverImmune carries out in oncology.

Developing a donor-based microbiome therapeutic product

Pilar Manrique Ronquillo, Research Scientist at Microviable Therapeuthics, talks about the donor-based microbiome therapeutic products research and development.

Enabling open science by open source solutions: FAIR data and expert consulting

Elisa Cirillo, team lead research data manager at The Hyve, talks about the importance of having high quality data and strong tools to improve the microbiome research and business.

IBD, Jeroen Raes: ‘We need to treat both the patient and the gut microbiota’

Jeroen Raes, from KU Leuven, Belgium, talks about the design of clinical trials for IBD patient with microbiome based therapies.

Future prospective of FMT in IBD treatment

Lihi Godny, from Rabin Medical Center in Israel, talks about the next steps research has to focus in to improve the FMT efficacy for IBD patients.

Engineer single strain LBPs for robust tumor microenvironment disruption

Pedro Correa de Sampaio, Chief Executive Officer at Neobe Therapeutics, talks about the challenges to remove immunosuppressive constraints that prevent the infiltration of immune cells in a subset of cancers.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top